CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer

PRIMARY OBJECTIVES:

I. To develop, test, and refine a CT perfusion protocol for its feasibility, reproducibility,
and quality with a limited number of patients with a pancreatic ductal adenocarcinoma (PDA).

II. To analyze preliminary date regarding perfusion parameters that improve accuracy in
predicting response and resectability for a subset of patients with locally advanced (LA) and
borderline resectable (BR) PDA treated with neoadjuvant therapy.

OUTLINE:

Patients undergo CT perfusion sequence over 30 seconds during the baseline standard of care
CT scan and during follow-up CT scans at 2 and possibly 4 months after chemotherapy, at 4-6
weeks after radiation therapy, or prior to definitive surgery.

After completion of the study, patients are followed up periodically for 2 years.

Inclusion Criteria:

- Signed informed consent form

- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma

Exclusion Criteria:

- Patients unable to provide informed consent

- Women who are pregnant or intending to become pregnant during the study

- Patients with body mass index greater than 40 kg/m^2

- History of severe allergic-like reaction to iodinated contrast media